Paradromics

Overview

Paradromics is a brain-computer interface (BCI) company based in Austin, Texas, founded in 2015. The company develops high-bandwidth neural interfaces designed to restore communication for people with paralysis and other neurological conditions. Paradromics' flagship product, the Connexus Microd Array, aims to provide the highest electrode count of any implantable BCI device, enabling high-fidelity neural signal recording and stimulation[@paradromics2024].

The company's mission is to create brain interfaces that can decode neural activity with sufficient bandwidth to restore natural communication for individuals with locked-in syndrome, [ALS](/diseases/amyotrophic-lateral-sclerosis), [spinal cord injury](/diseases/spinal-cord-injury), and other conditions that limit movement and speech.

Technology

The Connexus Microd Array

Paradromics' primary device is the Connexus Microd Array, featuring an unprecedented electrode count:

• Electrode Count: 65,000+ microelectrodes
• Array Size: 1mm × 1mm arrays with high-density recording sites
• Data Bandwidth: Very high (>1 Gbps neural data)
• Latency: <20 milliseconds
• Recording Capability: Single-unit neuron recording
• Wireless: Wireless data transmission and power

Technical Specifications

| Parameter | Specification |
|-----------|---------------|
| Electrode Density | 65,000+ / mm² |
| Signal Quality | Single-unit resolution |
| Power Consumption | <100 mW |
| Data Rate | >1 Gbps |
| Implant Size | Multiple 1mm arrays |

Hardware Architecture

...

Overview

Paradromics is a brain-computer interface (BCI) company based in Austin, Texas, founded in 2015. The company develops high-bandwidth neural interfaces designed to restore communication for people with paralysis and other neurological conditions. Paradromics' flagship product, the Connexus Microd Array, aims to provide the highest electrode count of any implantable BCI device, enabling high-fidelity neural signal recording and stimulation[@paradromics2024].

The company's mission is to create brain interfaces that can decode neural activity with sufficient bandwidth to restore natural communication for individuals with locked-in syndrome, [ALS](/diseases/amyotrophic-lateral-sclerosis), [spinal cord injury](/diseases/spinal-cord-injury), and other conditions that limit movement and speech.

Technology

The Connexus Microd Array

Paradromics' primary device is the Connexus Microd Array, featuring an unprecedented electrode count:

• Electrode Count: 65,000+ microelectrodes
• Array Size: 1mm × 1mm arrays with high-density recording sites
• Data Bandwidth: Very high (>1 Gbps neural data)
• Latency: <20 milliseconds
• Recording Capability: Single-unit neuron recording
• Wireless: Wireless data transmission and power

Technical Specifications

| Parameter | Specification |
|-----------|---------------|
| Electrode Density | 65,000+ / mm² |
| Signal Quality | Single-unit resolution |
| Power Consumption | <100 mW |
| Data Rate | >1 Gbps |
| Implant Size | Multiple 1mm arrays |

Hardware Architecture

The Paradromics system consists of:

Implantable Array: Multiple microelectrode arrays placed on the cortical surface

Headstage: Amplifies and digitizes neural signals

Wireless Link: Transmits data to external devices

Decoder Software: Translates neural signals into digital commands

Clinical Applications

Primary Focus

| Application | Target Condition | Status |
|-------------|-----------------|--------|
| Communication | [Locked-in syndrome](/diseases/locked-in-syndrome) | Development |
| Motor Restoration | [Spinal cord injury](/diseases/spinal-cord-injury) | Development |
| Speech Decoding | [ALS](/diseases/amyotrophic-lateral-sclerosis) | Development |
| Vision Restoration | Blindness | Research |

Target Diseases

[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis): Communication for late-stage patients

[Spinal Cord Injury](/diseases/spinal-cord-injury): Motor function restoration

[Stroke](/diseases/stroke): Rehabilitation and communication

[Parkinson's Disease](/diseases/parkinsons-disease): Movement decoding (future)

Competitive Advantages

Advantages

Highest Channel Count: 65,000+ electrodes vs. ~1,000 for competitors

High Bandwidth: Enables complex signal decoding

Low Latency: <20ms for real-time control

Wireless: Fully implantable system

Challenges

Early Stage: Preclinical/early clinical

Complexity: Manufacturing challenges

Regulatory: FDA approval pathway

Regulatory Status

• FDA Pre-Submission: Ongoing
• First-in-Human Trial: Planned 2026
• Breakthrough Device: Expected

Research Publications

Key Publications

Paradromics Research Team. [High-density neural interfaces for communication](https://paradromics.com/). 2024.

Cross-References

Related Companies

• [Neuralink](/companies/neuralink) - Competing BCI company
• [Blackrock Neurotech](/companies/blackrock-neurotech) - Competing BCI company
• [Synchron](/companies/synchron) - Competing BCI company

Related Technology Pages

• [Brain-Computer Interface Technology Landscape](/technologies/bci-technology-landscape)
• [Invasive Brain-Computer Interfaces](/technologies/invasive-bci)
• [Speech Neural Decoding BCI](/technologies/speech-neural-decoding-bci)

Related Disease Pages

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Spinal Cord Injury](/diseases/spinal-cord-injury)
• [Stroke](/diseases/stroke)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Locked-in Syndrome](/diseases/locked-in-syndrome)

See Also

• [BCI Companies](/companies/)
• [Neurotechnology](/technologies/)
• [Motor Cortex](/brain-regions/motor-cortex)

Clinical Applications

Communication Devices

• [Locked-in syndrome**: Restoring communication](/genes/cat)
• [ALS**: High-bandwidth AAC](/diseases/amyotrophic-lateral-sclerosis)
• [Stroke**: Rehabilitation support](/diseases/stroke)

Motor Prosthetics

• [Robotic arm control**: High-fidelity](/genes/ar)
• [Cursor control**: Computer interface](/genes/ace)
• [Speech synthesis**: Brain-to-text](/genes/th)

Technology Specifications

• [Connexus**: 1000+ channel array](/genes/ar)
• [Data rate**: High-bandwidth wireless](/genes/th)
• Longevity: Chronic implantation
• Size: Minimally invasive

Regulatory Status

• [FDA**: Breakthrough device designation](/genes/th)
• [Timeline**: First human trials 2025](/diseases/amyotrophic-lateral-sclerosis)
• [Approval**: Expected 2027+](/proteins/app)

Partnerships

• [UC Berkeley**: Research partnership](/genes/ar)
• [DARPA**: Next-generation BCI program](/technologies/bci-index)
• Medical centers: Clinical trial sites

References

Paradromics, Company Website (2024)